| scholarly article | Q13442814 |
| P2093 | author name string | Si-Young Kim | |
| Sun Kyung Baek | |||
| Hwi-Joong Yoon | |||
| Jae-heon Jeong | |||
| Kyung San Cho | |||
| P2860 | cites work | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer | Q33346628 | ||
| Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. | Q53667890 | ||
| Oxaliplatin: a review of preclinical and clinical studies. | Q54114691 | ||
| Rising incidence of adenocarcinoma of the esophagus and gastric cardia | Q68199481 | ||
| A phase II study of carboplatin in advanced or metastatic stomach cancer | Q68203508 | ||
| Phase II study of carboplatin in untreated inoperable advanced stomach cancer | Q68437200 | ||
| In vitro colony inhibition of carboplatin against stomach and lung cancer cell lines in comparison with cisplatin | Q70178442 | ||
| A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer | Q70753009 | ||
| Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group | Q72256279 | ||
| A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy | Q80371789 | ||
| A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study) | Q80789086 | ||
| A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status | Q82267815 | ||
| Phase II study of weekly paclitaxel and cisplatin combination therapy for advanced or recurrent gastric cancer | Q83059258 | ||
| Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan | Q83141983 | ||
| Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer | Q33366124 | ||
| A phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment | Q33369476 | ||
| Phase II study of sunitinib as second-line treatment for advanced gastric cancer | Q33389519 | ||
| A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer | Q33428751 | ||
| Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer | Q33488159 | ||
| Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer | Q34366342 | ||
| Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy | Q34547495 | ||
| S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial | Q34588472 | ||
| Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group | Q36619190 | ||
| Chemotherapy for metastatic gastric cancer: past, present, and future | Q37155553 | ||
| Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer | Q37222473 | ||
| Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study | Q37425848 | ||
| The efficacy of paclitaxel and cisplatin combination chemotherapy for the treatment of metastatic or recurrent gastric cancer: a multicenter phase II study | Q37477047 | ||
| Paclitaxel chemotherapy for the treatment of gastric cancer | Q37534441 | ||
| Is there a role for second-line chemotherapy in advanced gastric cancer? | Q37589204 | ||
| Docetaxel: its role in current and future treatments for advanced gastric cancer | Q37627676 | ||
| Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer. | Q40388526 | ||
| Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro | Q40389561 | ||
| In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines | Q40426495 | ||
| Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum | Q40508855 | ||
| Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy | Q40538283 | ||
| Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). | Q40613157 | ||
| Trends in cancer mortality in 15 industrialized countries, 1969-1986. | Q41121211 | ||
| Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials | Q42285715 | ||
| Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). | Q42937632 | ||
| A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen | Q43204489 | ||
| Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCO | Q43265427 | ||
| Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial | Q44153194 | ||
| Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism | Q45010010 | ||
| Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen | Q45185901 | ||
| Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes | Q46523462 | ||
| Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study | Q46569543 | ||
| Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer. | Q46708594 | ||
| A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer | Q46743013 | ||
| Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer. | Q46755330 | ||
| Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer. | Q46933491 | ||
| A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer | Q46960535 | ||
| Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. | Q48208260 | ||
| Cancer statistics, 1996. | Q50610104 | ||
| Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy. | Q50962533 | ||
| Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. | Q53521886 | ||
| Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. | Q53604465 | ||
| Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. | Q53610419 | ||
| Cancer Incidence in Korea. | Q53662243 | ||
| P433 | issue | 4 | |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 345-354 | |
| P577 | publication date | 2012-03-13 | |
| P1433 | published in | Gastric Cancer | Q15724608 |
| P1476 | title | Second-line chemotherapy for advanced gastric cancer in Korea | |
| P478 | volume | 15 |
| Q36085937 | Impact of the availability of active cytotoxic agents on the survival of patients with advanced gastric cancer |
| Q99365558 | LINC00641/miR-582-5p mediate oxaliplatin resistance by activating autophagy in gastric adenocarcinoma |
| Q33419166 | Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study |
Search more.